Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43889   clinical trials with a EudraCT protocol, of which   7298   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2022-002954-25
    Sponsor's Protocol Code Number:ASND0036
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2023-01-10
    Trial results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2022-002954-25
    A.3Full title of the trial
    ApproaCH: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children with Achondroplasia followed by an Open Label Extension period
    ApproaCH: Estudio multicéntrico, de fase 2b, a doble ciego, aleatorizado y controlado con placebo, para evaluar la seguridad y la eficacia de dosis subcutáneas de TransCon CNP administradas una vez por semana durante 52 semanas en niños con acondroplasia, seguido de un periodo de extensión abierto
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A phase 2b clinical trial to evaluate efficacy and safety of weekly doses of TransCon CNP compared with placebo in participants with achondroplasia aged 2 to 11 years of age
    Ensayo clínico de fase 2b para evaluar la seguridad y la eficacia de dosis semanales de TransCon CNP en comparación con placebo en participantes con acondroplasia de 2 a 11 años.
    A.3.2Name or abbreviated title of the trial where available
    A.4.1Sponsor's protocol code numberASND0036
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAscendis Pharma Growth Disorders A/S
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAscendis Pharma Growth Disorders A/S
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAscendis Pharma A/S
    B.5.2Functional name of contact pointClinical Trial Information Desk
    B.5.3 Address:
    B.5.3.1Street AddressTuborg Boulevard 12
    B.5.3.2Town/ cityHellerup
    B.5.3.3Post codeDK-2900
    B.5.4Telephone number004570222244
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/20/2299
    D.3 Description of the IMP
    D.3.1Product nameTransCon CNP 3.9 mg CNP-38/vial
    D.3.4Pharmaceutical form Powder and solvent for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 2413551-27-4
    D.3.9.2Current sponsor codeTransCon CNP
    D.3.9.3Other descriptive nameC-type natriuretic peptide conjugated to a multi-arm polyethylene glycol carrier molecule through a cleavable linker
    D.3.9.4EV Substance CodeSUB241143
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number3.9
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboPowder and solvent for solution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Achondroplasia (ACH) in prepubertal children
    Acondroplasia en niños prepúberes.
    E.1.1.1Medical condition in easily understood language
    Short-limbed dwarfism
    Enanismo de extremidades cortas.
    E.1.1.2Therapeutic area Diseases [C] - Musculoskeletal Diseases [C05]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 25.0
    E.1.2Level LLT
    E.1.2Classification code 10000452
    E.1.2Term Achondroplasia
    E.1.2System Organ Class 100000004850
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    • To evaluate efficacy of TransCon CNP on annualized growth velocity (AGV)
    Evaluar la eficacia de TransCon CNP en la velocidad de crecimiento anualizada (VCA).
    E.2.2Secondary objectives of the trial
    • To evaluate efficacy of TransCon CNP on height Z-score

    • To evaluate safety and tolerability of
    TransCon CNP

    • To evaluate pharmacokinetic properties of TransCon CNP

    • To assess potential immunogenic response to TransCon CNP
    • Evaluar la eficacia de TransCon CNP en la puntuación Z de la altura.

    • Evaluar la seguridad y la tolerabilidad de TransCon CNP.

    • Evaluar las propiedades farmacocinéticas de TransCon CNP.

    • Evaluar la posible respuesta inmunogénica de TransCon CNP.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Participants are eligible to be included in the trial only if all of the following criteria apply:
    1. Written, signed informed consent of the parent(s) or legal guardian(s) of the participant, and as required by the institutional review board/human research ethics committee/independent ethics committee (IRB/HREC/IEC).
    2. Male or female, between 2 and 11 years of age (inclusive) at the time of Screening.
    3. Clinical diagnosis of ACH with documented genetic confirmation available.
    4. Able to stand without assistance.
    5. Parent(s)/legal guardian(s) willing and able to administer weekly SC injections of IMP and to follow the protocol.
    6. At least six months of growth and disease history from ACHieve (TCC-NHS-01) trial or comparable growth and disease history available from medical records (pending confirmation by Medical Monitor).
    7. Considered eligible based on the medical history, physical examination, and the results of vital signs, ECG and clinical laboratory tests performed during the Screening period.
    Los participantes son aptos para participar en el estudio solo si cumplen todos los criterios siguientes:
    1. Consentimiento informado por escrito firmado del padre/la madre o los tutores legales del participante de acuerdo con los requisitos del comité de ética de la investigación con medicamentos (CEIm)/comité de ética de la investigación (CEI).
    2. Niño o niña de entre 2 y 11 años (inclusive) en el momento de la selección.
    3. Diagnóstico clínico de acondroplasia con confirmación genética documentada disponible.
    4. Capaces de estar de pie sin asistencia.
    5. El padre/la madre o los tutores legales deben estar dispuestos y ser capaces de administrar por vía SC las inyecciones semanales del PEI y de seguir el protocolo.
    6. Al menos seis meses de antecedentes de crecimiento y enfermedad obtenidos en el estudio ACHieve (TCC-NHS-01) o antecedentes de crecimiento y enfermedad comparables disponibles obtenidos de la historia clínica (pendiente de confirmación por el monitor médico).
    7. Se consideran aptos en función de la historia clínica, la exploración física y los resultados de las constantes vitales, el ECG y las pruebas de laboratorio clínico realizadas durante el periodo de selección.
    E.4Principal exclusion criteria
    Participants are excluded from the trial if any of the following criteria apply:
    1. Participation (i.e., signed informed consent) in any interventional clinical trial before within 3 months prior to screening.
    2. Closed epiphysis.
    3. Known or suspected hypersensitivity to the IMP or related products (trehalose, tris[hydroxymethyl]aminomethane, succinate, and mPEG).
    4. Have a growth disorder or medical condition other than ACH that results in short stature or abnormal growth such as severe ACH with developmental delay and acanthosis nigricans (SADDAN), hypochondroplasia, growth hormone deficiency, Turner syndrome, pseudoachondroplasia, inflammatory bowel disease, celiac disease, hypothyroidism, hyperthyroidism, pre-diabetes, or diabetes mellitus.
    5. Have received any dose of prescription medications and IMP or surgical intervention intended to affect stature, growth, or body proportionality at any time.
    6. Requires, or anticipated to require, chronic (> 4 weeks) or repeated treatment (more than twice/year and >3 weeks/year) with systemic corticosteroids during participation in the trial. Chronic use of high-dose inhaled corticosteroids is not allowed.
    7. Known history of presence of injury or disease of the growth plate(s), other than ACH, that affects growth potential of long bones.
    8. Known history of any bone-related surgery affecting growth potential of long bones, such as:
    • Orthopedic reconstructive surgery for bone lengthening (e.g., procedures for leg bowing such as 8-plate are not exclusionary).
    • Cervicomedullary decompression surgery without anticipated need for repeat decompression during the time of the trial are allowed with minimum of 6 months of bone healing.
    • Ventriculoperitoneal (VP) shunt and laminectomy with full recovery are allowed with minimum of 6 months of bone healing.
    • Bone fracture within 6 months prior to screening (within 2 months for fracture of digits and buckle fractures).
    9. Clinically significant findings at Screening, such as:
    • Expected to require surgical intervention during participation in the trial. Common surgeries, such as insertion of grommets, adenoidectomy, tonsillectomy, or myringotomy tube placement, are permitted.
    • Severe untreated sleep apnea or newly initiated sleep apnea treatment (e.g., Continuous Positive Airway Pressure [CPAP] in the previous 2 months prior to Screening.
    • Musculoskeletal disease, such as Salter-Harris fractures or clinical and/or radiographic evidence of severe hip pathology, or
    • Otherwise, are considered by the Investigator and Medical Monitor to make a participant unfit to receive trial treatment or undergo trial related procedures.
    10. Have evidence at Screening that are consistent with severe cervicomedullary junction compression based on clinical and/or radiologic findings that indicate immediate surgical intervention is required.
    11. Have a clinically significant finding or arrhythmia as determined by the investigator in consultation with the medical monitor that indicates abnormal cardiac function or conduction that includes, but is not exclusive to:
    • Repaired or unrepaired coarctation.
    • Moderate or greater complexity congenital heart disease including tetralogy of Fallot, Atrioventricular septal defects, truncus arteriosus, total anomalous pulmonary venous return, double outlet right ventricle, or single ventricle heart disease.
    12. QTcF ≥ 450 msec at the Screening Visit.
    13. Known history or presence of condition that impacts hemodynamic stability (such as autonomic dysfunction and orthostatic intolerance).
    14. Known history or presence of the following:
    • Chronic anemia (iron deficiency anemia that is resolved or adequately treated in the Investigator’s opinion is allowed).
    • Chronic renal insufficiency (GFR <60 mL/min/1.73 m2 for >3 months).
    • Chronic or recurrent illness that can affect hydration or volume status, including conditions associated with decreased nutritional intake or increased volume loss.
    15. Known history or presence of malignant disease.

    For full list of exclusion criteria, please see protocol.
    Los participantes quedan excluidos del estudio si cumplen alguno de los siguientes criterios:
    1. Participación (es decir, consentimiento informado firmado) en cualquier ensayo clínico intervencionista en los 3 meses anteriores a la selección.
    2. Epífisis cerrada.
    3. Hipersensibilidad conocida o sospecha de hipersensibilidad al PEI o productos relacionados (trehalosa, tris[hidroximetil]aminometano, succinato y MPEG).
    4. Tener un trastorno del crecimiento o afección médica distinta de acondroplasia que provoca talla baja o crecimiento anormal, tales como acondroplasia grave con retraso en el desarrollo y acantosis nigricans (SADDAN, por sus siglas en inglés), hipocondroplasia, deficiencia de la hormona del crecimiento, síndrome de Turner, seudoacondroplasia, enfermedad inflamatoria intestinal, enfermedad celíaca, hipotiroidismo, hipertiroidismo, prediabetes o diabetes mellitus.
    5. Haber recibido en algún momento cualquier dosis de algún medicamento obtenido con receta o de un medicamento en investigación o haberse sometido a una intervención quirúrgica cuyo objetivo fuera afectar a la estatura, al crecimiento o a la proporcionalidad corporal.
    6. Necesidad, actual o esperada, de tratamiento crónico (>4 semanas) o repetido (más de dos veces al año y >3 semanas al año) con corticoesteroides sistémicos durante la participación en el estudio. No se permite el uso crónico de corticoesteroides inhalados en dosis altas.
    7. Antecedentes conocidos o presencia de lesión o enfermedad de los cartílagos de crecimiento, aparte de la acondroplasia, que afectan al potencial de crecimiento de los huesos largos.
    8. Antecedentes conocidos de cualquier cirugía ósea que afecte al potencial de crecimiento de los huesos largos, tales como:
    • cirugía ortopédica reconstructiva para el alargamiento del hueso (p. ej., los procedimientos para el arqueo de las piernas, tales como placas en 8, no son excluyentes);
    • se permite la descompresión cervicomedular sin necesidad anticipada de repetir la descompresión durante el estudio con un mínimo de 6 meses de cicatrización ósea;
    • se permiten la derivación ventriculoperitoneal (VP) y la laminectomía con recuperación completa con un mínimo de 6 meses de cicatrización ósea;
    • fractura ósea en los 6 meses anteriores a la selección (2 meses en el caso de fracturas de los dedos y fracturas de toro).
    9. Hallazgos clínicamente significativos en la selección, tales como:
    • se espera que requieran una intervención quirúrgica durante la participación en el estudio. Se permiten las cirugías comunes, como la inserción de tubos de drenaje timpánicos, la adenoidectomía, la amigdalectomía o la colocación de tubos de miringotomía;
    • apnea del sueño grave no tratada o tratamiento de la apnea del sueño recién iniciado (p. ej., presión positiva continua en las vías respiratorias [CPAP, por sus siglas en inglés] en los 2 meses anteriores a la selección);
    • enfermedad musculoesquelética, como fracturas de Salter-Harris o evidencia clínica o radiográfica de patología grave de la cadera; u
    • otra causa que el investigador y el monitor médico consideren que incapacita al participante para recibir el tratamiento del estudio o para someterse a los procedimientos relacionados con el mismo.
    10. Tener indicios en la selección que sean compatibles con una compresión grave de la unión cervicomedular basados en resultados clínicos o radiológicos que indiquen que se requiere una intervención quirúrgica inmediata.
    11. Tener un resultado clínicamente significativo o una arritmia, según determine el investigador tras consultarlo con el monitor médico, que indiquen una función o conducción cardiaca anormal que incluya, entre otras cosas, lo siguiente:
    • coartación reparada o no reparada;
    • cardiopatía congénita de complejidad moderada o mayor, que incluye tetralogía de Fallot, comunicación auriculoventricular, tronco arterioso, retorno venoso pulmonar anómalo total, doble salida del ventrículo derecho o cardiopatía de ventrículo único.
    12. QTcF ≥450 ms en la visita de selección.
    13. Antecedentes conocidos o presencia de una afección que afecte a la estabilidad hemodinámica (como la disfunción autonómica y la intolerancia ortostática).
    14. Antecedentes conocidos o presencia de alguna de las siguientes enfermedades:
    • anemia crónica (se permite la anemia ferropénica resuelta o adecuadamente tratada a criterio del investigador);
    • insuficiencia renal crónica (FG <60 ml/min/1,73 m2 durante >3 meses);
    • enfermedad crónica o recurrente que pueda afectar a la hidratación o a la volemia, incluidas las afecciones asociadas a la disminución de la ingesta nutricional o al aumento de la pérdida de volumen.
    15. Antecedentes conocidos o presencia de enfermedad maligna.

    Para obtener una lista completa de los criterios de exclusión, consulte el protocolo.
    E.5 End points
    E.5.1Primary end point(s)
    Annualized growth velocity (AGV) at Week 52
    Velocidad de crecimiento anualizada (VCA) en la semana 52.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Annualized growth velocity (AGV) will be evaluated at Week 52
    La velocidad de crecimiento anualizada (VCA) se evaluará en la semana 52.
    E.5.2Secondary end point(s)
    • Change from baseline in height Z-score at Week 52

    • Incidence of TEAEs and safety assessments (safety labs, vital signs, physical examination, 12-lead ECG, and radiographic assessments)

    • Plasma concentration of Total, Free CNP and mPEG

    • Detection and characterisation of ADAs
    • Cambio con respecto al valor basal en la puntuación Z de altura en la semana 52.
    • Incidencia de acontecimientos adversos surgidos durante el tratamiento (AAST) y evaluaciones de seguridad (pruebas de laboratorio de seguridad, constantes vitales, exploración física, ECG de 12 derivaciones y evaluaciones radiográficas).
    • Concentración plasmática total y libre de CNP y de MPEG.
    • Detección y caracterización de los anticuerpos contra el fármaco.
    E.5.2.1Timepoint(s) of evaluation of this end point
    • Change from baseline in height Z-score will be evaluated at week 52

    • Incidence of TEAEs will be evaluated at each visit and safety assessments (safety labs, vital signs, physical examination, 12-lead ECG, and radiographic assessments) will be evaluated, dependant on procedure, at screening and weeks 0, 4, 12, 26, 39, 52, 56, 64, 78, 91, 104 and 109

    • Plasma concentration of Total, Free CNP and mPEG will be evaluted at weeks 4, 12, 26, 39, 52, 56, 64, 78, 91 and 104

    • Detection and characterisation of ADAs will be evaluated at weeks 0, 4, 12, 26, 39, 52, 56, 64, 78, 91, 104 and 109
    • El cambio con respecto al valor basal en la puntuación Z de altura se evaluará en la semana 52.
    • La incidencia de AAST se evaluará en cada visita y se harán evaluaciones de seguridad (pruebas de laboratorio de seguridad, constantes vitales, exploración física, ECG de 12 derivaciones y evaluaciones radiográficas), en función del procedimiento, en la selección y en las semanas 0, 4, 12, 26, 39, 52, 56, 64, 78, 91, 104 y 109.
    • La concentración plasmática total y libre de CNP y de MPEG se evaluará en las semanas 4, 12, 26, 39, 52, 56, 64, 78, 91 y 104.
    • La detección y caracterización de los anticuerpos contra el fármaco se evaluará en las semanas 0, 4, 12, 26, 39, 52, 56, 64, 78, 91, 104 y 109.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E. trial design description
    Periodo aleatorizado seguido de una extensión abierta.
    Randomised period followed by open label extension
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA3
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    New Zealand
    United States
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Última visita del último sujeto.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 80
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F. of subjects for this age range: 80
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) No
    F.1.2.1Number of subjects for this age range: 0
    F.1.3Elderly (>=65 years) No
    F.1.3.1Number of subjects for this age range: 0
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state4
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 32
    F.4.2.2In the whole clinical trial 80
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    No plans for treatment after the Open Label Extension Period has ended.
    No hay planes de tratamiento después de que el periodo de extensión abierto haya finalizado.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2023-05-24
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2023-05-09
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands